The paper investigates a potential cause of a type of severe epilepsy that develops in early life because of a defect in a gene called KCNQ2. The significance is fundamental because it substantially ...
Hemogenyx Pharmaceuticals plc, a publicly traded company headquartered in London, announced the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed/refractory (R/R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback